Indaptus Therapeutics (INDP) investor relations material

Company overview and business model

• Clinical-stage biotechnology company focused on systemically-administered anti-cancer and anti-viral immunotherapies using patented bacterial-based technology.

• Lead candidate Decoy20 targets both innate and adaptive immune responses, showing broad anti-tumor and anti-viral activity in preclinical models.

• As of Q2 2026, all clinical studies for Decoy20 have been discontinued, and the company is evaluating strategic alternatives, including partnerships, licensing, or new research initiatives.

• Recent research collaborations include work with Kunming University of Science and Technology on neurological and sleep research.

Financial performance and metrics

• Multiple financings completed between August 2024 and June 2026, including direct offerings, private placements, and convertible notes, raising over $19 million gross.

• Reverse stock split (1-for-28) implemented in June 2025 to maintain Nasdaq listing.

• ATM offering in September 2025 raised $2.3 million; equity line with Yorkville terminated in March 2026 after $1.74 million net proceeds.

Use of proceeds and capital allocation

• No proceeds will be received from the resale of shares by selling stockholders; all proceeds go to selling stockholders.

• Company intends to retain all available funds for business operations and does not anticipate paying dividends.